This article is an erratum on:
Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation
Frontiers Production Office*An Erratum on
Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation
By Mimura Y, Mimura-Kimura Y, Saldova R, Rudd PM and Jefferis R (2022) Front. Immunol. 13:818382. doi: 10.3389/fimmu.2022.818382
Due to a production error, the measuring unit “ml” was incorrectly changed to “μl” during the production process.
A correction has been made to the section Methods, subsection Preparation of Glycan Oxazolines:
“The glycan donors sialoglycan oxazoline (S2G2-Ox), galactosylated glycan oxazoline (G2-Ox), and nongalactosylated glycan oxazoline (G0-Ox) were prepared from sialylglycopeptide (SGP) (Tokyo Chemical Industry Co. Ltd.) in a modified version of the previously described method (32). Briefly, SGP (20 mg) dissolved in 100 μl of 50 mM phosphate (pH 6.0) was digested at 37°C for 8 h with EndoS-coupled Sepharose-4 that had been prepared by coupling EndoS to CNBr-activated Sepharose-4 (GE Healthcare) to release sialoglycan, according to the manufacturer’s instruction. For G2-Ox and G0-Ox preparation, SGP (40 mg) was digested with EndoS-coupled Sepharose-4 and neuraminidase (2 U, Roche) overnight and the supernatant containing the desialylated glycan was divided into two aliquots, with one for preparation of G2-Ox and the other for G0-Ox. For the latter, the galactosylated glycan was digested with β (1-3,4)-galactosidase (Agilent) at 37°C for 48 h. The glycan in each aliquot (~100 μl) was converted to glycan oxazoline by the addition of 2-chloro-1,3-dimethylimidazolinium chloride (23.4 mg) and triethylamine (47.2 µl) on ice for 1 h. The reaction was diluted with 4 ml of butanol:ethanol:water (4:1:1, v/v/v) and purified on cellulose column (2 ml in a Poly-Prep Chromatography Column, Bio-Rad) equilibrated with the same solution (33). After washing the column with 12 ml of the solution and 2 ml of absolute ethanol, glycan oxazoline was eluted with distilled water. The glycan-containing fractions were detected with anthrone/sulfuric acid and dried under vacuum.”
The publisher apologizes for this mistake. The original version of this article has been updated.
Keywords: glycoengineering, antibody-dependent cellular cytotoxicity, intravenous immunoglobulin, autoimmune disease, natural killer cell, Fcγ receptor, oligosaccharide
Citation: Frontiers Production Office (2022) Erratum: Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation. Front. Immunol. 13:902018. doi: 10.3389/fimmu.2022.902018
Received: 22 March 2022; Accepted: 22 March 2022;
Published: 01 April 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org